<p class="first" id="d2499900e280">Traditionally, the main indication for cardiopulmonary
exercise testing (CPET) in
heart failure (HF) was for the selection of candidates to heart transplantation: CPET
was mainly performed in middle-aged male patients with HF and reduced left ventricular
ejection fraction. Today, CPET is used in broader patients' populations, including
women, elderly, patients with co-morbidities, those with preserved ejection fraction,
or left ventricular assistance device recipients, i.e. individuals with different
responses to incremental exercise and markedly different prognosis. Moreover, the
diagnostic and prognostic utility of symptom-limited CPET parameters derived from
submaximal tests is more and more considered, since many patients are unable to achieve
maximal aerobic power. Repeated tests are also being used for risk stratification
and evaluation of intervention, so that these data are now available. Finally, patients,
physicians and healthcare decision makers are increasingly considering how treatments
might impact morbidity and quality of life rather than focusing more exclusively on
hard endpoints (such as mortality) as was often the case in the past. Innovative prognostic
flowcharts, with CPET at their core, that help optimize risk stratification and the
selection of management options in HF patients, have been developed.
</p>